Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Therapeutic vaccine for treatment of genital herpes enters phase 2.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1744. No abstract available.

PMID:
23980267
2.

Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(8):2141-2. No abstract available.

PMID:
25580483
3.

Vical initiates vaccine trials against HSV-2 and CMV.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(2):255. No abstract available.

PMID:
24963522
4.

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N.

Vaccine. 2012 Nov 19;30(49):7046-51. doi: 10.1016/j.vaccine.2012.09.057. Epub 2012 Oct 4.

5.

A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.

Mo A, Musselli C, Chen H, Pappas J, Leclair K, Liu A, Chicz RM, Truneh A, Monks S, Levey DL, Srivastava PK.

Vaccine. 2011 Nov 3;29(47):8530-41. doi: 10.1016/j.vaccine.2011.07.011. Epub 2011 Jul 19.

PMID:
21767588
6.

Potential for immunotherapy in the treatment of herpesvirus infections.

Bernstein DI.

Herpes. 2001 Mar;8(1):8-11. Review.

PMID:
11867010
7.

Immunostimulatory CpG treatment for genital HSV-2 infections.

Herbst MM, Pyles RB.

J Antimicrob Chemother. 2003 Dec;52(6):887-9. Epub 2003 Oct 29. Review. No abstract available.

PMID:
14585849
8.

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial.

Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, Lekstrom J, Cox E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L.

J Infect Dis. 1997 Nov;176(5):1129-34.

PMID:
9359709
9.

Development of a therapeutic vaccine for HSV-2.

Hosken NA.

Vaccine. 2005 Mar 18;23(17-18):2395-8.

PMID:
15755634
10.

Shingles vaccine: who should get it?

Johnson AM.

S D Med. 2006 Aug;59(8):349-50. No abstract available.

PMID:
16941852
11.

Construction, characterization and immunogenicity of a glycoprotein E negative bovine herpesvirus-1.1 Egyptian strain "Abu-Hammad".

El-Kholy AA, Rady DI, Abdou ER, Elseafy MM, Abdelrahman KA, Soliman H.

J Virol Methods. 2013 Dec;194(1-2):74-81. doi: 10.1016/j.jviromet.2013.07.041. Epub 2013 Aug 17.

PMID:
23962750
12.

Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons.

Wald A, Koelle DM, Fife K, Warren T, Leclair K, Chicz RM, Monks S, Levey DL, Musselli C, Srivastava PK.

Vaccine. 2011 Nov 3;29(47):8520-9. doi: 10.1016/j.vaccine.2011.09.046. Epub 2011 Sep 21.

PMID:
21945262
13.

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Moutschen M, Léonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M.

Vaccine. 2007 Jun 11;25(24):4697-705. Epub 2007 Apr 18.

PMID:
17485150
14.

Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.

Alving CR, Rao M, Steers NJ, Matyas GR, Mayorov AV.

Expert Rev Vaccines. 2012 Jun;11(6):733-44. doi: 10.1586/erv.12.35. Review.

PMID:
22873129
15.

Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.

Manservigi R, Boero A, Argnani R, Caselli E, Zucchini S, Miriagou V, Mavromara P, Cilli M, Grossi MP, Balboni PG, Cassai E.

Vaccine. 2005 Jan 4;23(7):865-72.

PMID:
15603886
16.

CDX-1401 combined with TLR agonist: positive phase 1 results.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1742. No abstract available.

PMID:
23980263
17.

Vaccine helps thwart herpes in women.

[No authors listed]

AIDS Read. 2000 Oct;10(10):574. No abstract available.

PMID:
11068791
18.

An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson S, Bravo FJ, Bernstein DI, Flechtner JB, Long D.

J Virol. 2013 Apr;87(7):3930-42. doi: 10.1128/JVI.02745-12. Epub 2013 Jan 30.

19.

Herpes zoster vaccine (Zostavax).

[No authors listed]

Med Lett Drugs Ther. 2006 Sep 11;48(1243):73-4.

PMID:
16977285
20.

Herpes simplex virus type 2 vaccines: new ground for optimism?

Aurelian L.

Clin Diagn Lab Immunol. 2004 May;11(3):437-45. Review.

Supplemental Content

Support Center